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Effect of high dose ramipril with or without indomethacin on glomerular barrier has an intrinsic renal toxicity [3] and
glomerular selectivity. its reduction by pharmacological manipulations that re-
Background. Despite the accumulating evidence of their ef-
duce protein traffic is renoprotective both in experimen-ficacy, angiotensin-converting enzyme inhibitors (ACEi) still
tal [4] and human chronic nephropathies [5]. In particu-provide imperfect renoprotection. Up-titration above conven-
tional doses and combined therapy with other antiproteinuric lar, antihypertensive drugs have been used in humans to
agents may serve to achieve renoprotection in patients at risk slow or even halt the progression of renal disease in dia-
of rapid disease progression.
betic [6] and non-diabetic [7, 8] proteinuric glomerulopa-Methods. The effect of maximum tolerated ACEi doses (ram-
thies. Angiotensin I-converting enzyme inhibitors (ACEi)ipril 15 mg/day, range 5 to 20) alone or combined with indo-
methacin (75 mg  2/day) on urinary protein excretion (UPE) ameliorate proteinuria and glomerular size-selective func-
and glomerular barrier size-selective function was evaluated in tion and give more renal protection than other antihyper-19 patients with chronic non-diabetic nephropathies and persis-
tensive drugs for the same level of blood pressure controltent proteinuria.
Results. Maximum ramipril doses decreased UPE more ef- either in experimental animals and humans [4–8]. How-
fectively than non-ACEi therapy. Proteinuria reduction was ever, except for type 1 diabetic nephropathy, ACEi, at the
associated with significant reduction (50%) of the non-selec- doses currently employed in human nephropathies, lowertive glomerular membrane shunt, but did not correlate with
proteinuria by only 20 to 50% as compared to pre-treat-concomitant changes in arterial pressure and renal hemo-
dynamics, nor was it influenced by treatment duration. The ment [5]. This possibly explains why a substantial propor-
reduction in UPE and sieving coefficient of the largest neutral tion of patients still progresses to end-stage renal disease
dextrans exceeded by twofold the reduction achieved by con-
(ESRD) despite their being on ACEi for years [5].ventional ACEi doses in historical controls with similar renal
A goal for the future is to find the way to increase thedysfunction and proteinuria, previously studied under identical
experimental conditions. Indomethacin did not influence renal antiproteinuric effect of ACEi further and to extend the
effects of maximum ramipril doses and was prematurely with- number of patients who effectively respond to ACEi ther-drawn in six patients because of reversible side effects. Serum
apy [9]. Data are available that this can be safely achievedpotassium significantly increased only in combination with in-
domethacin and never required treatment withdrawal. by enhancing the ACEi dose above those recommended
Conclusions. Up-titration to maximally tolerated doses safely by manufacturers to treat arterial hypertension [10]. Thus,
increases ACEi antiproteinuric effect and may serve to achieve
to maximize renoprotection ACEi can be up-titrated overmaximum renoprotection in the long-term. Combination with
the doses required to normalize blood pressure (BP)indomethacin is poorly tolerated and ineffective. Innovative
approaches are needed to use ACEi more effectively. using instead urinary protein as a target [5, 11, 12]. It is
still unclear, however, whether the antiproteinuric effect
of maximum tolerated doses of ACEi is sustained by a
Heavy, persistent proteinuria is associated with unfa- direct amelioration of the glomerular size-selective func-
vorable outcome in diabetic [1] and non-diabetic chronic
tion and whether it can be further enhanced by other anti-renal disease [2]. Enhanced protein traffic through the
proteinuric drugs [13]. Recently, more proteinuria reduc-
tion has been safely achieved by combining a short-course
Key words: ACE inhibition, non-diabetic nephropathies, dextran frac-
of the non-steroidal anti-inflammatory drug (NSAID)tional clearance, glomerular size-selectivity, proteinuria, progressive
renal disease. indomethacin [14, 15] to conventional doses of an ACEi
in patients with IgA nephropathy and sub-nephrotic pro-
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Fig. 1. Schematic representation of the study design.
prolonged course of indomethacin to an up-titrated the outpatient clinic of the Unit of Nephrology, Ospedali
Riuniti di Bergamo. At screening evaluation, they hadACEi to maximum tolerated doses. In the long term this
might translate to more effective renoprotection, which persistent urinary proteins 3 g/24 h despite concomit-
ant ACEi therapy for at least six months, and were with-may be of major clinical relevance particularly for pa-
tients who remain at an increased risk of rapid disease out evidence of urinary tract infection or overt heart
failure (New York Heart Association class III or more).progression because of persistent nephrotic range protein-
uria despite treatment with conventional ACEi doses. Exclusion criteria were: treatment with corticosteroids,
NSAIDs, or immunosuppressive drugs in the previous sixThus, in patients with chronic non-diabetic nephropa-
thies and long lasting nephrotic syndrome, we evaluated months; acute myocardial infarction or cerebrovascular
disease in the previous six months; severe uncontrolledwhether the antiproteinuric effect of maximum tolerated
ACEi doses is safely enhanced by indomethacin. Second- hypertension (diastolic BP 115 mm Hg and/or systolic
BP220 mm Hg); evidence or suspicion of renovasculararily, the antiproteinuric effect of the maximum tolerated
doses was compared with that of non-ACEi therapy. disease, obstructive uropathy, diabetes mellitus, collagen
disease, cancer, abnormal serum aminotransferase con-In parallel with the evaluation of urinary proteins, the
fractional clearance of neutral dextrans of graded size centrations, or chronic cough; drug or alcohol abuse; preg-
nancy, breast feeding, or ineffective contraception. Writ-were measured to evaluate whether, and to what extent,
the observed changes in urinary proteins were related ten informed consent was obtained before study entry.
to concomitant changes in glomerular barrier size-selec-
Study designtive function.
Figure 1 summarizes the study design. After screening
evaluation, eligible patients entered a two-month wash-
METHODS
out period from previous treatment with ACEi or angio-
Patients and definitions tensin II receptor antagonists, and a one-month washout
from other antihypertensives. Non-potassium sparing di-Nineteen patients with non-diabetic chronic nephrop-
athy and heavy persistent proteinuria were recruited from uretics and occasional administration of sublingual nifed-
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ipine were allowed as deemed clinically appropriate Sample size
to maintain fluid balance and diastolic blood pressure The primary efficacy variable of our study was the
90 mm Hg. No change was introduced in the patients’ 24-hour urinary protein excretion rate. A previous study
previous diet, particularly in the daily protein and sodium found that indomethacin added to conventional ACEi
intake. Nifedipine, however, was not allowed during doses in 10 patients with non-nephrotic proteinuria in-
urine collection in order not to affect the urinary protein duced a 48% reduction (from 2.3 1.1 to 1.2 1.1 g/24 h)
excretion rate measurements. Arterial blood pressure in the urinary protein excretion rate [17]. Predicting—on
(measured in triplicate in the sitting position after 5 min- the basis of the analyses of all patients with nephrotic
utes of rest) and 24-hour urinary protein excretion rate range proteinuria (urinary protein excretion rate 3
(mean of 3 consecutive measurements) were measured g/24 h) attending our out-patient clinic—a baseline uri-
nary protein excretion rate of 6.0  2.3 g/24 h, andevery two weeks during the entire study period. At the
assuming, conservatively, as clinically relevant a 40%end of the washout period, patients underwent a renal
reduction with the combined indomethacin and ramiprilclearance study (baseline) to evaluate glomerular filtra-
therapy versus ramipril alone, it was estimated that totion rate (GFR), renal plasma flow (RPF), and fractional
give this study an 80% power to detect such reductionsclearance of neutral dextrans and albumin. Then, the
as statistically significant (P  0.05, two sided test), thepatients entered an eight-week up-titration period, the
predicted difference in the primary efficacy variable, ataim of which was to identify the maximum tolerated dose
least 10 patients had to complete the study.of ramipril in each individual patient. To this purpose,
ramipril (Hoechst Marion Roussel S.p.A, Milan, Italy)
Clearance studieswas weekly up-titrated from a starting dose of 2.5 mg/
Glomerular filtration rate and RPF were measuredday to 5, 7.5, 10, 15, and 20 mg/day (maximum toler-
by inulin and paraaminohippuric acid (PAH) clearance,ated dose). One week after each increase of the study
respectively, under a steady state of water diuresis in-drug, blood pressure, serum creatinine and potassium
duced by oral water loading according to a previously de-values were measured. When diastolic blood pressure
scribed procedure [17–19]. The same protocol was useddecreased below 70 mm Hg, the study drug was not
for each patient during the five renal clearance studies.up-titrated further to prevent the risk of symptomatic
Briefly, after induction of diuresis, a primed infusion ofhypotension. In cases of symptomatic hypotension, se-
inulin (Inutest; Fresenius Pharma, Graz, Austria) andrum creatinine increase by more than 30% after any
PAH (Jacopo Monico, Mestre, Italy) was followed bydose-increase of the study drug, or hyperkalemia, the
slow intravenous administration of neutral dextran testdose was decreased to the previous level. At the end
macromolecules (130 mg/kg, Dextran-40, Rheomacro-of the ramipril up-titration period, the renal clearance
dex; Pharmacia, Uppsala, Sweden) during 10 to 15 min-studies were performed with the same modality of base-
utes. A sustained infusion of inulin and PAH was thenline evaluation. Thereafter the patients entered a cross-
started to maintain constant plasma concentrations of
over phase of two treatment periods in a random se-
both tracers. Approximately 15 minutes after the priming
quence: (a) two month therapy with the ACEi ramipril dose of inulin and PAH, the study drug was adminis-
alone at the maximum tolerated dose; (b) indomethacin tered. After an equilibration period of about 40 minutes,
(75 mg twice daily) added to the maximum tolerated three exactly-timed urine collections of 40 minutes each
dose of ramipril. At the end of each treatment period were made by spontaneous voiding for evaluating GFR,
of the crossover phase, the renal clearance studies were RPF, and albumin and neutral dextran fractional clear-
repeated. After the crossover phase, ramipril and indo- ance (1st clearance period). Blood samples were collected
methacin were withdrawn, and the patients entered a at the beginning and at the end of each clearance period.
two-month recovery phase, at the end of which renal Blood pressure was monitored with the patient in a su-
clearance studies were again performed. pine position before solute administration and during
each clearance period. Urine and plasma samples were
Study aim used to determine inulin, PAH, albumin, and neutral
The primary aim of the study was to evaluate the dextran concentrations.
changes in urinary proteins and glomerular barrier size- Inulin and PAH concentrations in plasma and urine
selectivity induced by four weeks of treatment with indo- samples were determined with colorimetric assays as pre-
methacin added to the maximum tolerated doses of rami- viously described [17–19]. Separation of graded-size dex-
pril versus maximum tolerated doses alone (Study A). tran molecules and inulin in plasma and urine samples
Secondarily, the study was aimed to compare the effects was performed by gel permeation chromatography on a
of maximum tolerated doses of ramipril with those of Sephacryl S-300 column (1.6  95 cm) using dextran
standards of known molecular weight (Pharmacosmos,non-ACEi therapy (Study B).
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Viby Sj., Denmark) for column calibration. Molecular kidneys) using an established model of glomerular ultra-
filtration [24]. The intrinsic membrane permeability pa-radii of individual dextran fractions were calculated ac-
cording to Oliver et al, as previously described [18–20]. rameters were calculated as shown previously [17, 18],
and the sum of squared errors between experimental andDextran concentrations in eluted fractions were deter-
mined using the anthrone reaction [21] and fractional calculated sieving coefficients was minimized at single
patient level during each clearance study. The approachclearance of dextran molecules was computed as:
that we used for calculating these intrinsic membrane
D  (U/P)D/(U/P)In [1] parameters separates their effects on sieving coefficients
from those owing to changes in GFR, RPF, oncotic pres-where (U/P)D and (U/P)In are the urine-to-plasma con-
centration ratios of dextran and inulin, respectively. sure, and glomerular transmembrane hydraulic pressure
difference (P). This theoretical approach requires theMean GFR, RPF, filtration fraction (FF), and albumin
fractional clearance were calculated using standard for- assumption of glomerular transmembrane hydraulic
pressure difference (P) that cannot be directly mea-mulas as the average value of the three clearance periods,
and normalized for body surface area. To take into ac- sured in humans. In keeping with previous studies [18],
we assumed P 45 mm Hg in these patients at baselinecount incomplete renal extraction of PAH, an assumed
renal extraction coefficient equal to 0.7 and 0.8 was conditions, a value slightly elevated above what is be-
lieved to be a normal value (40 mm Hg), to take intoadopted for corresponding mean GFR lower or higher
than 80 mL/min/1.73 m2, respectively [22]. consideration the moderate hypertension that character-
izes our patient population. Because in experimental
Other laboratory assays models of glomerular disease ACEi have been shown to
selectively decrease glomerular capillary pressure [25],Total protein concentration in 24-hour urine samples
was measured by an automatic analyzer (Synchron CX5; we assumed a value of P  40 mm Hg for theoretical
Beckman Instruments, Fullerton, CA, USA). Other lab- analysis of sieving coefficients measured at the end of
oratory measurements [serum albumin, potassium, total the treatment periods.
cholesterol, high density lipoprotein (HDL) cholesterol,
Statistical analysistriglycerides as well as urinary sodium and urea excre-
tion] were done using routine laboratory techniques. Data are expressed as mean SD or median and range,
as specified. Data were subjected to two-way ANOVA,
Analysis of glomerular membrane transport based on and significance of multiple pair-wise comparisons was
pore theory determined using an unpaired t test with the Bonferroni
We investigated intrinsic glomerular membrane per- correction [26]. Primary comparison (study A) was maxi-
meability properties of macromolecules using a mathe- mum ramipril tolerated doses alone versus maximum
matical model of glomerular size-selectivity described in ramipril tolerated doses combined to indomethacin. Sec-
detail previously [18, 23]. This model simulates glomeru- ondary comparisons (study B) were maximum ramipril
lar filtration of neutral test macromolecules on the basis tolerated doses versus basal and recovery.
of assumed membrane permeability properties and mea- Statistical significance level was defined as P  0.05.
sured determinants of glomerular ultrafiltration. The Statistical analysis was performed using the SAS Soft-
model assumes that the glomerular membrane is perfora- ware (Release 8; SAS Institute Inc., Cary, NC, USA).
ted by cylindrical pores having a bimodal distribution of
their radii. The radius of restrictive membrane pores is
RESULTSassumed to have a log normal probability distribution.
Eleven male and 8 female patients, between 18 to 67In parallel with selective pores, a shunt pathway con-
years old, were selected for study participation fromsisting of large pores that do not restrict the passage of
February 1998 to December 1998. Eight had systoliclargest test macromolecules is also assumed [23]. This
(SBP 140 mm Hg) and diastolic blood pressure (DBPprobability distribution function of pore radii is therefore
90 mm Hg) in normal ranges without antihypertensivecharacterized by three adjustable parameters: u, s, and
therapy and eleven were hypertensive. Renal biopsy had	0. The parameters u and s represent the mean and the
been performed in 17 patients: 6 were diagnosed withstandard deviation of the log-normal pore-size distribu-
membranous nephropathy, 4 membranoproliferative ne-tion, respectively, and 	0 represents the fraction of ultra-
phropathy, 4 IgA nephropathy, and 3 focal segmentalfiltrate that would pass through the shunt if plasma pro-
glomerulosclerosis.teins were absent. The model is based on another freely
Of the 19 patients recruited, three were withdrawn atadjustable parameter, the ultrafiltration coefficient (Kf),
different time points during the study because of renalwhich is the product of hydraulic permeability and filter-
cancer, myocardial infarction (during the recovery phase),ing surface area of the glomerular membrane. We calcu-
lated Kf (for the entire glomerular population of both and progressive worsening of renal function up to ESRD
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Table 1. Demographic and clinical data at screening evaluation perkalemia (serum potassium between 5.5 and 6 mEq/L)
Gender M/F 9/7 occurred only in 2 out of 16 patients during the combined
Age years 36 (18–67) treatment with ramipril and indomethacin (Table 5) No
Systolic BP mm Hg 135 (110–173)
major change in serum lipid profile was reported duringDiastolic BP mm Hg 82 (64–110)
Mean BP mm Hg 100 (81–127) the study phases, although a significantly lower mean
Urinary protein excretion g/24 h 5.5 (3.5–18.4) serum total cholesterol value was observed at the end of
Serum creatinine mg/dL 1.55 (0.60–3.65)
the combined ramipril plus indomethacin treatment than
Data are mean (range). in the ramipril titration and recovery phases (Table 5).
Changes in GFR were significantly correlated with uri-
nary sodium excretion during the combined treatment
with ramipril and indomethacin (r  0.61, P 0.01), butdespite stopping ramipril treatment. Main characteristics
at study entry (screening evaluation) of the 16 patients not during treatment with ramipril alone (r  0.43, P 
0.11). Indomethacin had to be withdrawn before comple-who completed the study are given in Table 1. All these
patients were on diuretic therapy (5 with loop diuretics, tion of the two-month combined treatment with ramipril
in six patients because of dyspepsia refractory to symp-9 with thiazides, and 2 with both). Renal function, as
serum creatinine, ranged from normal to moderate renal tomatic treatment (N  2), edema (N  2), somnolence
(N  1), and serum creatinine increase 30% versusinsufficiency. The median (range 5 to 20 mg/day) dose
of ramipril at the end of the up-titration phase was 15 baseline (N  1). The adverse events fully reversed and
all patients recovered after indomethacin withdrawal.mg/day (that is, threefold the antihypertensive dose rec-
ommended at the time the present study was designed).
Study B. Comparative analyses versus baselineSpecifically, seven patients reached safely the highest
scheduled up-titration (20 mg/day). Up-titration was Clinical parameters. Twenty-four hour proteinuria at
the end of the maximum tolerated ramipril dose periodstopped in five patients before the maximum target be-
cause their diastolic blood pressure values had decreased significantly decreased as compared to baseline (mean
reduction 29%) and fully recovered after ramipril with-to 70 mm Hg or less, and in two because of symptomatic
hypotension. Patients who did not complete as compared drawal (Table 2). Although differences were not statis-
tically significant, proteinuria reduction tended to beto those who completed the up-titration phase had a
lower mean arterial pressure value at baseline (104  greater (45 to 50%) in patients treated with furosemide
alone or in combination with thiazides, than in those10 vs. 116  7 mm Hg, P  0.034) and during treatment
with ramipril alone (90  4 vs. 95  6 mm Hg, P  treated with thiazides alone (about 20%). SBP, DBP,
and MAP followed a similar trend, with only a partial0.069) or in combination with indomethacin (94  10 vs.
110  9 mm Hg, P  0.006). These differences were not recovery of SBP after ramipril withdrawal (Table 3).
Neither changes in proteinuria and blood pressure wereassociated with differences in urinary sodium excretion.
During the following two treatment periods with maxi- significantly associated with urinary sodium excretion
(data not shown). The GFR significantly decreased withmum ramipril doses alone or combined to indomethacin,
each patient was maintained on the dose of ramipril maximum tolerated ramipril dose and only partially re-
covered after ramipril withdrawal (Table 4). At variance,achieved at the end of the up-titration period.
RPF and filtration fraction (FF) did not change signifi-
Study A. Comparative analyses between treatment cantly throughout the three study periods (Table 4).
with ramipril alone or combined to indomethacin Albeit the change did not achieve statistical significance,
mean albumin fractional clearance numerically decreasedEfficacy assessment. Proteinuria, SBP, DBP, mean ar-
terial pressure (MAP), renal hemodynamic parameters, with the maximum tolerated ramipril dose and fully re-
covered after ramipril withdrawal (Table 4). Urinaryalbumin fractional clearance, and the sieving profile of
dextran molecules, measured at the end of the treatment sodium, potassium, and urea excretion did not change
significantly through out the three considered periodsperiod with maximum tolerated dose of ramipril alone
or combined to indomethacin were comparable (Tables (Table 2).
Neutral dextran fractional clearance. Sieving coeffi-2 to 4 and Fig. 2). The above parameters, with the excep-
tion of GFR, also were comparable at the end of the cients of neutral dextran molecules of graded sizes (20
to 70 A˚) measured in the basal condition, at the end oftreatment period with ramipril maximum tolerated doses
and of the up-titration period. the maximum tolerated ramipril dose, and after the re-
covery period are reported in Figure 3. Fractional clear-Safety assessment. With maximum tolerated doses of
ramipril alone or combined with indomethacin, the mean ances of small dextran molecules (radii 36 A˚) were
not significantly affected by maximum tolerated dose ofserum potassium was significantly higher than at base-
line, but none of the patients had to be withdrawn from ramipril as compared to baseline. Sieving coefficients of
larger dextran molecules (radii 36 to 70 A˚) were sig-the study because of refractory hyperkalemia. Mild hy-
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Table 2. Urinary protein, sodium, potassium, and urea excretion at baseline, at the end of ramipril titration phase (titration), at the maximum-
tolerated ramipril dose (MR), at the indomethacin plus maximum-tolerated ramipril dose (MR
Ind), and after recovery
Baseline Titration MR MR
Ind Recovery
Protein excretion rate g/24 h 5.61.6 4.01.4ab 4.02.2ab 3.92.1ac 5.11.9
Sodium excretion mEq/24 h 19993 17282 195107 18483 18190
Potassium excretion mEq/24 h 64.317.1 61.321.0b 66.227.5 65.722.9 73.621.6
Urea excretion g/24 h 22.57.4 19.05.9 19.57.5 21.86.5 20.76.9
Data are mean  SD.
a P  0.01 vs. baseline
b P  0.05 and c P  0.01 vs. recovery
Table 3. Systolic, diastolic and mean blood pressure measured at with unrestricted sodium intake. These changes did not
baseline, at the end of ramipril titration phase (titration), at the
correlate with concomitant reduction in arterial bloodmaximum-tolerated ramipril dose (MR), at the indomethacin plus
maximum-tolerated ramipril dose (MR
Ind), and after recovery pressure or with any concomitant change in renal hemo-
dynamics, nor were they influenced by treatment dura-Baseline Titration MR MR
Ind Recovery
tion. However, although differences were not statistically
SBP mm Hg 14216 12914b 12813b 13014a 13311a
significant, proteinuria reduction was almost double inDBP mm Hg 8911 7812bc 769bd 8111b 859
MAP mm Hg 10712 9512bc 9310bc 9712b 1019a patients treated with loop diuretics than in those treated
Data are mean  SD. Abbreviations are: SBP, systolic blood pressure; DBP, with thiazides.
diastolic blood pressure; MAP, mean arterial pressure. Previous studies found a further reduction in urin-a P  0.05 and b P  0.01 vs. baseline
c P  0.05 and d P  0.01 vs. recovery ary proteins when other antiproteinuric drugs, such as
NSAIDs, mostly indomethacin [16], were given in combi-
nation with conventional ACEi doses. Indomethacin ef-
fectively reduces proteinuria in experimental animals
nificantly decreased with maximum tolerated ramipril [27] and in nephrotic patients [14, 15], and has comple-
doses as compared to baseline, and almost completely mentary effects to ACEi on membrane permeability [28]
recovered after ramipril withdrawal (radii 64 to 70 A˚). and contrasting effects on glomerular hemodynamics
Theoretical analysis of glomerular size-selective func- [29]. Here, we found no further reduction in urinary
tion. Dextran sieving coefficients and renal hemody-
protein excretion nor in the glomerular sieving coeffi-
namic parameters were used as input data for the theo-
cients of small and large neutral dextran macromoleculesretical analysis of glomerular size-selective function in
when patients were receiving the combined therapy forthe different phases of the study. The results of the theo-
eight weeks, as compared to ramipril alone at maximumretical analysis are reported in Table 6. While the change
dose. This contrasts with previous findings that the addi-did not achieve statistical significance, the calculated val-
tion of indomethacin to an ACEi at a conventional doseues of Kf, mean pore radius (u) and the spreading (s) of regimen offered additive antiproteinuric effect in pa-the pore-distribution numerically increased with maxi-
tients with renal disease [16]. Differences in treatmentmum tolerated ramipril dose as compared to baseline
duration of indomethacin and in dose regimen of ACEivalues, and fully recovered after ramipril withdrawal
that are not therapeutically equivalent, as for the antipro-(Fig. 4).We also calculated the shunt parameter 	0 that
teinuric effect, may account for different outcomes onwas reduced by more than 59% by maximum tolerated
proteinuria of the combined therapy observed in theramipril dose as compared to baseline and partially re-
present study. Conceivably, a longer treatment periodcovered after ramipril withdrawal (29%; Table 6 and
might have been more effective. However, eight weeksFig. 4).
is a relatively standard period that is sufficient to achieve
the maximum antiproteinuric effects with other drugs
DISCUSSION such as ACE inhibitors or angiotensin II receptor antag-
onists. Moreover, without a substantial effect on urinaryThe results of the present study show that in patients
proteins, a prolonged treatment period might offer onlywith non-diabetic chronic nephropathies and long-last-
marginal benefits that might be overwhelmed by theing, persistent nephrotic proteinuria, indomethacin added
potential risks of more nephrotoxicity. Regardless of theto maximum tolerated doses (up to 20 mg/day, on aver-
involved mechanisms, besides being ineffective as anti-age 15 mg/day) of ramipril, does not further ameliorate
proteinuric agent, indomethacin was not well toleratedproteinuria and glomerular size-selectivity and is poorly
and tended to decrease the GFR in patients with lesstolerated. However, maximum tolerated doses of rami-
sodium intake, which adds a further safety concern on thepril ameliorated both proteinuria and size selective func-
tion as compared to non-ACEi therapy, even in patients validity of combined therapy in patients with proteinuric
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Table 4. Kidney functional parameters at baseline, at the end of ramipril titration phase (titration), at the maximum-tolerated ramipril dose
(MR), at the indomethacin plus maximum-tolerated ramipril dose (MR
Ind), and after recovery
Baseline Titration MR MR
Ind Recovery
GFR mL/min/1.73 m2 5631 5123 4525ab 5028 4823a
RPF mL/min/1.73 m2 442280 464241c 392209b 435269 373220
FF % 147 124c 124 124 146
Albumin FC 103 2.491.83 1.721.65 1.691.09 1.861.61 2.431.73
Data are mean  SD. Abbreviations are: GFR, glomerular filtration rate; RPF, renal plasma flow; FF, filtration fraction; FC, fractional clearance.
a P  0.05 vs. baseline
b P  0.05 vs. titration
c P  0.05 vs. recovery
Fig. 2. (A and B) Fractional clearance of neu-
tral dextran macromolecules as a function of
effective molecular radius measured at the
end of the ramipril titration phase (titration;
), at the maximum-tolerated ramipril dose
phase (MR; ), and of the indomethacin
plus maximum-tolerated ramipril dose phase
(Ind
MR; ). The continuous line represents
calculated fractional clearance according to the
log normal
 shunt model and optimal param-
eter values.
Table 5. Serum potassium, total and high-density lipoprotein (HDL) cholesterol, and triglycerides at baseline, at the end
of the ramipril titration phase (titration) at the maximum-tolerated ramipril dose (MR), at the indomethacin plus
maximum-tolerated ramipril dose (MR
Ind), and after recovery
Baseline Titration MR MR
Ind Recovery
Serum potassium mEq/L 4.20.5 4.40.6 4.50.4 4.80.5abc 4.40.4
Serum total cholesterol mg/dL 27796 291108c 279101 267112bc 313134
Serum HDL cholesterol mg/dL 53.414.5 55.318.8 51.917.2 52.414.6 56.313.8
Serum triglycerides mg/dL 18899 183137 199137 178124 213142
Data are mean  SD.
a P  0.01 vs. baseline
b P  0.05 vs. titration
c P  0.05 vs. recovery
chronic nephropathies already on maximum tolerated the relative importance of the non-selective shunt path-
way, as indicated by mean change in calculated shuntACEi doses. Moreover, the blood pressure tended to be
higher during combined ramipril-indomethacin therapy parameter (	0; Fig. 4) which is responsible for the passage
of circulating macromolecules into the urinary space.than during therapy with ramipril alone. This might have
offset, at least in theory, some of the antiproteinuric ef- Thus, maximum ACE inhibition decreased urinary pro-
tein excretion by ameliorating the glomerular size-selec-fects of indomethacin.
On the other hand, theoretical analysis of dextran tive function.
In addition, maximum tolerated ramipril doses al-fractional clearance values showed that maximum toler-
ated ramipril doses, as compared to non-ACEi therapy, lowed a remarkable reduction (27%) in proteinuria to be
achieved versus the screening evaluation, when patientshad little effect on the mean (u) and the distribution (s)
of membrane pore-radii, but reduced by more than 50% were on chronic treatment with conventional ACEi doses.
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Fig. 3. (A and B) Fractional clearance of neu-
tral dextran macromolecules as a function of
effective molecular radius measured at base-
line (), at the end of the maximum-tolerated
ramipril dose (MR; ), and after recovery
(). The continuous line represents calculated
fractional clearance according to the log nor-
mal 
 shunt model and optimal parameter
values. *P  0.05 and **P  0.01 vs. MR.
Table 6. Assumed and calculated glomerular membrane permeability parameters at baseline, at the end of ramipril titration phase (Titration),
at the maximum-tolerated ramipril dose (MR), at the indomethacin plus maximum-tolerated ramipril dose (MR
Ind), and after recovery
Baseline Titration MR MR
Ind Recovery
P mm Hg 45 40 40 40 45
Kf mL/min/mm Hg 2.181.37 2.511.52 2.442.32 2.621.69 1.891.16
u A˚ 54.311.2 53.08.1 50.68.1 54.07.1 54.98.1
s A˚ 1.160.11 1.160.07 1.190.07 1.150.06 1.150.08
	0 103 13.010.4 6.85.3 5.33.7a 5.83.1 9.23.9b
Data are mean  SD. Abbreviations are: P, mean transmembrane pressure difference; Kf, ultrafiltration coefficient; u, mean pore size; s, standard deviation of
corresponding normal probability distribution; 	0, shunt parameter.
a P  0.05 vs. Baseline
b P  0.01 vs. MR
Fig. 4. Log-normal probability distribution
of glomerular membrane pore-size and mean
group shunt parameter (0) at baseline, at the
end of the maximum-tolerated ramipril dose
phase (MR), and after recovery.
However, since neutral dextran clearances were not mea- a previous series of patients given ACEi for a similar pe-
riod of time (10 weeks) with similar mean (range) serumsured at screening evaluations, the present study could
not demonstrate that this effect was sustained by a fur- creatinine concentration [1.3 (1.1 to 3.9) mg/dL] and
proteinuria [5.6 (0.7 to 13.3) g/24 h] at study inclusion,ther amelioration of glomerular size-selective function.
To address this issue, we compared the effect of maxi- and evaluated under the same experimental conditions
(that is, by using the same clearance procedures andmum ACEi with that of conventional doses evaluated in
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analytical methods to measure changes in proteinuria, blood pressure is probably the right target. Nephrolo-
GFR, RPF and glomerular barrier permeability parame- gists should now abandon indomethacin when ACEi are
ters) [19]. These comparative analyses showed that, de- used properly.
spite an identical reduction (11.5%) in mean arterial
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and GFR, and is most likely dependent on enhanced
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slits [30]. Altogether these findings may have major clini-
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